Cancer testing firm VolitionRx Ltd (NYSE:VNRX) has raised US$8.4mln gross via its previously announced public offering, now closed.
It issued 3.5mln shares at US$2.40 a share.
"Volition intends to use the net proceeds of the offering for continued product development, clinical studies, product commercialization, working capital, and other general corporate purposes," it said in the brief stock market statement Tuesday.
Oppenheimer & Co Inc. acted as the sole book-running manager.
Shares closed on Tuesday at US$2.34 each.